OBJECTIVES: The possible @entity8619 (OLP) is the subject of an ongoing and controversial discussion in the literature. The main criticism of studies on this subject relates to the lack of sufficient data to support the initial diagnosis of OLP in cases that finally developed into @entity957 . We describe the possible premalignant character of OLP and @entity75 ( @entity75 ) of a prospectively followed cohort of @entity1 with detailed documentary data. STUDY DESIGN: A study group of 173 @entity1 , 62 @entity1 diagnosed with OLP and 111 @entity1 with @entity75 , according to revised, modified World Health Organization diagnostic criteria, was followed up from 6.6 to 72.0 months (mean, 31.9 months). The expected number of @entity1 with @entity5 in the group of @entity1 with OLP and in the group of @entity1 with @entity75 was estimated by comparing the number of @entity1 , their ages, sex, and the length of follow-up to annual incidence rates of @entity5 for the general Dutch population, to explore the possibility of coincidental @entity189 . The binomial test was used to determine whether the observed number of cases of @entity5 in the OLP group and the @entity75 group exceeded the expected numbers. RESULTS: Three of 173 @entity1 (1.7%), 2 @entity1 and 1 @entity1 , developed @entity957 of the oral mucosa during follow-up. All malignant transformations occurred in the @entity75 group. The annual malignant transformation rate, based on a mean follow-up of 31.9 months, was calculated as 0.65% per year. A comparison of the expected against actual figures for the development of @entity189 revealed no increase in @entity1 with OLP and a 219-fold increase in @entity1 with @entity75 , with the latter not statistically significant, but with a P value of .083, suggesting at least a trend. CONCLUSION: Our results give support to the hypothesis that @entity1 with @entity75 have an increased risk of @entity5 , but this increased risk was not detected in our sample of @entity1 with OLP. Before a final statement with regard to the premalignant character of OLP and @entity75 can be formulated, the present follow-up study should be prolonged and expanded with a larger number of @entity1 . Until then, we advise that @entity1 with OLP and @entity75 should undergo biannual follow-up examinations. Follow-up will be particularly important in @entity1 with @entity75 who have @entity1066 .

The possible premalignant XXXX : a prospective study.

@entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'men'] @entity75 :: ('MESH:D001927', 'Disease') :: ['oral lichenoid lesions', 'OLL'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'oral cancer'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'squamous cell carcinomas'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['atrophic/erosive/ulcerative lesions'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas'] @entity8619 :: ('MESH:D017676', 'Disease') :: ['malignant transformation of oral lichen planus']
@entity8619 :: (MESH:D017676,Disease) :: ['character of oral lichen planus and oral lichenoid lesions']
